XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income (loss) $ 144,661 $ (1,065,145)
Discontinued operations 495,410 818,273
Net income (loss) from continuing operations (350,749) (1,883,418)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 1,227,607 1,152,062
Share-based compensation 162,960 264,574
Decrease in non-cash contingent consideration (280,020) (543,006)
Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy (76,300) 548,261
Noncash interest expense 13,833 11,333
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (171,584) 2,014,438
Inventories 1,868,350 706,102
Other current assets and other assets 507,102 545,256
Accounts payable and other current liabilities (1,311,123) (2,394,824)
Other long-term liabilities (299,937) (865,109)
Net cash provided by (used in) operating activities from continuing operations 1,290,139 (444,331)
Discontinued operations 495,410 1,332,870
Net cash provided by operating activities 1,785,549 888,539
Cash flows from investing activities:    
Additions to property and equipment (19,458) (22,726)
Note receivable investment funding (200,000) 0
Additions to intangible assets (98,883) (548,435)
Net cash used in investing activities (318,341) (571,161)
Cash flows from financing activities:    
Borrowings on line of credit 15,000,000 18,500,000
Repayments on line of credit (15,000,000) (18,500,000)
Cash payment of contingent consideration (995,277) (260,735)
Repurchase of subsidiary shares from noncontrolling interest 0 (800,000)
Repurchase of common shares (302,802) (442,544)
Net cash used in financing activities (1,298,079) (1,503,279)
Net increase (decrease) in cash and cash equivalents 169,129 (1,185,901)
Cash and cash equivalents at beginning of period 24,753,796 28,212,635
Cash and cash equivalents at end of period $ 24,922,925 $ 27,026,734